[1] Authier N,Gillet JP, Fialip J,et al.Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats[J].Neurotox Res,2001,3(3):301-306.
[2] Desai NP,Trieu V,Hwang LY,et al.Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status[J].Anticancer Drugs, 2008,19(9):899-909.
[3] Ibrahim NK,Desai N,Legha S,et al.Phase I and pharmacokinetic study of ABI-007, a Cremophor free, protein-stabilized, nanoparticle formulation of paclitaxel[J].Clin Cancer Res,2002, 8(5):1038-1044.
[4] Mross K, Holländer N, Hauns B,et al.The pharmacokinetics of a 1-h paclitaxel infusion[J].Cancer Chemother Pharmacol,2000,45(6): 463-470.
[5] Gardner ER,Dahut WL,Scripture CD,et al.Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel[J].Clin Cancer Res,2008,14(13): 4200-4205.
[6] Sparreboom A,Scripture CD,Trieu V, et al.Comparative preclinical and clinical pharmacokinetics of a Cremophor-free,nanoparticles albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)[J].Clin Cancer Res,2005, 11(11): 4136-4143.
[7] Nyman DW,Campbell KJ,Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticles formulation of paclitaxel in patients with advanced nonhematologic malignancies[J].J Clin Oncol,2005,23(31):7785-7793.
[8] Gardner ER,Dahut WL,Scripture CD,et al.Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel[J].Clin Cancer Res,2008,14(13): 4200-4205.
[9] Desai N,Trieu V,Yao Z,et al.Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free,albumin-bound paclitaxel,ABI-007,compared with cremophor-based paclitaxel[J].Clin Cancer Res,2006,12(4):1317-1324.
[10] Chin D,Boyle GM,Williams RM,et al.Novel markers for poor prognosis in head and neck cancer[J].Int J Cancer,2005,113(3):789-797.
[11] Koukourakis MI,Giatromanolaki A,Brekken RA,et al.Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients[J].Cancer Res,2003,63(17):5376-5380.
[12] Watkins G,Douglas-Jones A,Bryce R,et al.Increased levels of SPARC(osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent[J].Fatty Acids,2005,72(4):267-272.
[13] Ibrahim NK,Samuels B,Page R,et al.Multicenter Phase II trial of ABI-007,an albumin-bound paclitaxel, in women with metastatic breast cancer[J].J Clin Oncol,2005, 23(25):6019-6026.
[14] Blum JL,Savin MA,Edelman G,et al.Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes[J]. Clin Breast Cancer,2007,7(11):850-856.
[15] Gradishar WJ,Tjulandin S,Davidson N,et al.Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol 2005,23(31):7794-7803.
[16] Roy V,LaPlant BR,Gross GG,et al.North Central Cancer Treatment Group, NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)[J].J Clin Oncol, 2007,25 (18S): 1048.
[17] Lobo C,Lopes G,Baez O,et al. Final results of a phase II study of nab-paclitaxel,bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer(MBC)[J].Breast Cancer Treat,2010,123(2):427-435.
[18] Mirtsching B,Cosgriff T,Harker G,et al.A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer [J] Clin Breast Cancer,2011,11(2):121-128.
[19] Conlin AK,Hudis CA, Bach A,et al.Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)[J].J Clin Oncol,2009,27(Suppl 15s):abstract 1006.
[20] Rivera MP. Multimodality therapy in the treatment of lung cancer [J].Semin Respir Crit Care Med,2004,25 (Suppl 1) :3-10.
[21] 杭达明,谢国栋,张葆春. GP 方案与 TP 方案一线治疗晚期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2008,13 (2):133-136.
[22] Rizvi NA,Riely GJ,Azzoli CG,et al.Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer[J].J Clin Oncol,2008,26(4):639-643.
[23] Lee CB,Stinchcombe TE,Socinski MA,et al.Phase I trial of escalating doses of ABI-007 (nanoparticle albumin-bound paclitaxel) and gemcitabine in patients (pts) with thoracic malignancies[J]. J Clin Oncol,2007,25 (18S): 18094.
[24] Green MR,Manikhas GM,Orlov S,et al.Abraxane,a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer[J].Ann Oncol,2006,17(8):1263-1268.
[25] Reynolds C,Barrera D,Jotte R,et al.Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer[J].J Thorac Oncol,2009,4(12):1537-1543.
[26] Socinski MA,Manikhas GM,Stroyakovsky DL,et al.A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2010,5(6):852-861.
[27] Dudek AZ,Nguyen S.Safety of nab-paclitaxel plus sunitinib: analysis of three cases[J].Anticancer Res, 2008,28(5B):3099-3105.
[28] Bradley DA, Hussain M. Promising novel cytotoxic agents and combinations in metastatic prostate cancer[J].Cancer,2008,14(1): 15-19.
[29] Hersh EM,O'Day SJ,Ribas A,et al.A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma[J].Cancer,2010,116(1):155-163. |
